Ian Taylor Sells 9,020 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now owns 159,121 shares in the company, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Arvinas Stock Performance

Arvinas stock opened at $17.26 on Friday. The business’s 50-day simple moving average is $18.37 and its two-hundred day simple moving average is $22.72. The company has a market cap of $1.19 billion, a PE ratio of -6.23 and a beta of 1.88. Arvinas, Inc. has a fifty-two week low of $16.07 and a fifty-two week high of $51.51.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the company earned ($2.53) EPS. As a group, analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently made changes to their positions in ARVN. T. Rowe Price Investment Management Inc. purchased a new stake in Arvinas in the fourth quarter valued at $42,332,000. Norges Bank acquired a new position in shares of Arvinas in the 4th quarter valued at about $23,845,000. Boxer Capital Management LLC purchased a new stake in shares of Arvinas in the fourth quarter worth about $20,294,000. Braidwell LP grew its holdings in Arvinas by 148.3% during the third quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock worth $31,637,000 after acquiring an additional 767,242 shares during the period. Finally, RTW Investments LP raised its position in Arvinas by 19.8% during the fourth quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock valued at $63,919,000 after acquiring an additional 551,979 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Wall Street Analyst Weigh In

ARVN has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. BTIG Research began coverage on shares of Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price target on the stock. Oppenheimer upped their price target on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Guggenheim reissued a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a research report on Wednesday, February 12th. Finally, Stephens started coverage on Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 target price on the stock. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.